Shire withdraws EU filing of Daytrana for ADHD with no plans to resubmit
This article was originally published in Scrip
Executive Summary
Shire has withdrawn its EU marketing application for its ADHDtransdermal patch product, Daytrana (methylphenidate transdermal system) for use in children, licensed from Noven. There are no plans to resubmit the filing.